Publications

Original Research Articles

  1. Sidhu J, Rojavin M, Pfister M, Edelman J. Enhancing patient flexibility of subcutaneous IgG dosing: pharmacokinetic outcomes of various maintenance and loading regimens. Biologics in Therapy 2014 (In press).
  2. Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B. Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watking P, Morrison T, Gillespie W, Gordon MR, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T. Modeling and simulation for medical product development and evaluation: Highlights from the FDA-C-Path-ISOP 2013 workshop. (2014) J PHARMACOKINET PHAR, 41:545-52.
  3. Rojavin M, Sidhu J, Pfister M, Hubsch A. Subcutaneous immunoglobulin loading regimens for Previously untreated patients with primary antibody deficiency. (2014) CLIN EXP IMMUNOL, 178 Suppl 1:146-8.
  4. Leil T, Frost C, Wang X, Pfister M, LaCreta F. Model-Based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e136; doi:10.1038/psp.2014.34.
  5. Defronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36: 3169-3176.
  6. Landersdorfer C, Bexon M, Edelman J, Rojavin M, Kirkpatrick CMJ, Lu J, Pfister M, Sidhu J. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgraduate Medicine. 2013; 125, November 2013 doi: 10.3810/pgm.2013.112712.
  7. Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, Lacreta FP, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013; 76: 432-444.
  8. Van der Walt JS, Hong Y, Zhang L, Pfister M, Boulton DW, Karlsson MO. A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment. CPT Pharmacometrics Syst Pharmacol. 2013 May 8;2:e42. doi: 10.1038/psp.2013.20.
  9. Naik H, Lu J, Cao C, Pfister M, Vakilynejad M, Leifke E. Pharmacometric approaches to guide dose selection of the novel GPR40 agonist TAK-875 in subjects with type 2 diabetes mellitus. CPT Pharmacometrics Syst Pharmacol. 2013 Jan 9;2:e22. doi: 10.1038/psp.2012.23.
  10. Zhang L, Boulton DW, Pfister M. A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin. J Clin Pharmacology 2012; 52: 126S-133S.
  11. Zhou Z, Shen J, Hong Y, Kaul S, Pfister M, Roy A. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012; 92: 251-257.
  12. Maclean JR, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011; 7: 149-156.
  13. Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. Antimicrob Agents Chemother. 2011; 55: 5746-5752.
  14. Yoshitsugu H, Sakurai T, Ishikawa H, Roy A, Bifano M, Pfister M, Seriu T, Hiraoka M. Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. Diagn Microbiol Infect Dis. 2011; 70: 91-100.
  15. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011; 33: 1798-1808.
  16. Kasichayanula S, Liu X, Zhang W, Pfister M, Reele SB, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011; 13: 770-773.
  17. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13: 47-54.
  18. Leil T, Feng Y, Zhang L, Mohan P, Pfister M. Quantification of apixaban's therapeutic utility to select the phase 3 dose for prevention of venous thromboembolism. Clinical Pharmacol Therapeutics 2010 88: 375-382.
  19. Zhang L, Feng Y, List J, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycemic control and body weight. Diabetes Obesity Metabolism 2010; 12: 510-516.
  20. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M. Application of individualized bayesian urea kinetic modeling to pediatric hemodialysis. ASAIO J 2010; 56: 246-253.
  21. Stone J, Banfield C, Pfister M, Allerheiligen S, et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacology 2010; 50: 20S-30S.
  22. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacol Therapeutics 2009; 85:513-519.
  23. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Pfister M. Dapagliflozin, a novel SGLT inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacol Therapeutics 2009; 85: 520-526.
  24. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. A model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 2009; 53: 2346-2353.
  25. Zhu M, Bifano M, Xu X, Wang Y, LaCreta F, Grasela D, Pfister M. Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. Antimicrob Agents Chemother 2008; 52: 2836-2841.
  26. Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacology 2008; 48: 1254-1269..
  27. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacology 2007; 47: 1408-1420.
  28. Rohatagi S, Krishnaswami S, Pfister M, Sahasranaman S. Model based covariate pharmacokinetic analysis and lack of cortisol suppression by a new inhaled corticosteroid, ciclesonide using a novel cortisol release model. Am J Therapeutics 2005; 12: 385-397.
  29. Shi J, Pfister M, Jenkins SG, Chapel S, Ambrose P, Howard DR. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia. Clinical Pharmacokinetics 2005; 44: 317-329.
  30. Cottagnoud P, Pfister M, Acosta F, Cottagnoud M, Flatz L, Kuehn F. Daptomycin is highly efficacious against penicillin-resistant and penicilllin- and quinolone-resistant pneumococci in experimental meningitis, sterilizing the CSF within four hours. Antimicrob Agents Chemother 2004; 48: 3928-3933.
  31. Pfister M, Uehlinger DE, Hung A, Schaedeli F, Sheiner LB. A new Bayesian method to forecast and calibrate individual hemodialysis dose. Hemodialysis International 2004, 8: 244-256.
  32. Pfister M, Martin N, Haskell LP, Barrett JS. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacology 2004; 44: 1-11.
  33. Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Taeuber M. Evaluation of ertapenem, a new long acting carbapenem, against penicillin-sensitive and -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2003; 47: 1943-1947.
  34. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett K, Rosenkranz S, Sheiner LB. Pharmacokinetic interactions between efavirenz and co-administered protease inhibitors in AACTG Trial 398. Antimicrob Agents Chemother 2003; 47: 130-137.
  35. Pfister M, Zhang L, Sheiner LB, Hammerlund-Udendas M, Taeuber M, Cottagnoud P. Modeling of transfer kinetics at the serum-CSF barrier in experimental meningitis: application to grepafloxacin. Antimicrob Agents Chemother 2003; 47: 138-143.
  36. Cottagnoud P, Acosta F, Cottagnoud M, Pfister M, Taeuber M. Efficacy of BMS 284756 against penicillin-sensitive, penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002; 46: 184-187.
  37. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE-inhibition and angiotensin II receptor blockade. J Hypertension 2002; 20: 125-130.
  38. Lu JF, Pfister M, Ferrari P, Wang Y, Sheiner LB. Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. Clinical Pharmacokinetics 2002; 41: 1105-1113.
  39. Pfister M, Labbe L, Lu JF, Hammer SM, Mellors J, Bennett K, Rosenkranz S, Sheiner LB. Effect of co- administration of nelfinavir, indinavir and saquinavir on the pharmacokinetics of amprenavir in AACTG Trial 398. Clinical Pharmacol Therapeutics 2002; 72: 133-141.

Review Articles

  1. Tortorici MA, Cutler D, Zhang L, Pfister M. Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function. J Clin Pharmacology 2012; 52: 109S-118S.
  2. Zhang L, Pfister M, Meibohm B. Quantitative pharmacology: concepts and challenges of model-based drug development. AAPS J 2008; 10: 552-529.
  3. Barrett JS, Labbe L, Pfister M. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clinical Pharmacokinetics 2005; 44: 591-625.
  4. Kenna L, Labbe L, Barrett JS, Pfister M. Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J 2005; 7: 390-407.

Book Chapters and Special Issues of Journals

  1. Pfister M. Chapter on “Pharmacometrics in Chronic Kidney Disease”. In the text book Applications in Pharmacometrics published by Springer, September 2014.
  2. Pfister M, D’Argenio D. The emerging scientific discipline of pharmacometrics. Co-Editor, special issue of J Clin Pharmacology 2010 (pp 1-156).
  3. Arya V, Pfister M, Nolin T. Therapeutics in kidney disease: challenges, innovations, opportunities. Co- Editor, special issue of J Clin Pharmacology 2012 (pp 1-140).

Editorials

  1. Pfister M, Mager D, Holford N, Corrigan C, Tannenbaum S, Bruno R, Zhang L. The International Society of Pharmacometrics. J Pharmacokinet Pharmacodyn 2013; 40: 3-4.
  2. Pfister M, Mager D. The American Conference on Pharmacometrics 2013. J Pharmacokinet Pharmacodyn 2013; 40: 1.
  3. Pfister M, Nolin RD, Arya V. Optimizing drug development and use in patients with kidney disease: opportunities, innovations, and challenges. J Clin Pharmacology 2012; 52: 4S.
  4. Fissell R, Schulman G, Pfister M, Zhang L, Hung AM. Novel dialysis modalities: Do we need new metrics to optimize treatment? J Clin Pharmacology 2012; 52: 72S-78S.
  5. Nolin TD, Arya V, Sitar DS, Pfister M. Optimizing drug development and use in patients with kidney disease. J Clin Pharmacology 2011; 51: 628-630.
  6. Pfister M, Whaley JM, Zhang L, List JF. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther 2011; 89: 621-625.
  7. Suryawanshi S; Zhang L, Pfister M, Meibohm B. The Current Role of Model-based Drug Development. Expert Opinion Drug Discovery 2010; 5: 311-321.
  8. Zhang L, Ng C, List J, Pfister M. Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium–glucose cotransporter-2 inhibition. J Clin Pharmacology 2010; 50: 113S-120S.
  9. D’Argenio D, Pfister M. The emerging scientific discipline of pharmacometrics. J Clin Pharmacology 2010; 50: 6S.
  10. Pfister M, Brundage R, Gastonguay M, Miller R, Tannenbaum S, D’Argenio D. Defining the Future of Pharmacometrics: The American Society of Pharmacometrics. J Clin Pharmacology 2010; 50: 158S.

 

Marc Pfister

Professor

 

  • DEPARTMENTSystems Pharmacology and Pharmacometrics Medical Faculty, University of Basel

  • COUNTRYSwitzerland